As we've mentioned in previous posts, we were paid in stock (50k shares) and cash ($10k) to run a promotion for TPIV in Sept/Oct of 2014.  Saw this "valuation" from See Through Equity (who we are not involved with) suggesting that the $13.3 million grant that Mayo Clinic was given by the DOD to research TPIV's breast cancer Phase II trial will have a huge impact on the valuation of the company.  See the full article here from yahoo finance - http://finance.yahoo.com/news/seethruequity-issues-company-tapimmune-highlighting-130000827.html